Digging Into The Data: Boston Scientific Corporation (NYSE:BSX)

18

Boston Scientific Corporation (NYSE:BSX) closed its last session at $27.43. The stock traded within a range of $27.16 and $27.99. The company operates in the Healthcare sector with a market capitalization of 37.63 Million. Trading volume for Boston Scientific Corporation was 8.98 Million in its previous trading session. Currently, Boston Scientific Corporation (NYSE:BSX) has an average volume of 8.98 Million.

Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral arterial disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors.

Analyst Views

Boston Scientific Corporation (NYSE:BSX) received a Buy rating from 4 analysts. 0 analysts gave its stock an Outperform rating. 5 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.

Boston Scientific Corporation (NYSE:BSX) touched its 1-Year High price of $29.93 on 10/23/17 and its 1-Year Low price of $23.03 on 02/23/17.

EPS & Financials

Boston Scientific Corporation (NYSE:BSX) reported its EPS in the last quarter as $0.31/Share lagging the analyst estimate of $0.31/Share by a difference of $0. This showed a surprise of 0% in the last quarter earnings.

For the current quarter, 22 analysts are projecting a mean EPS of $0.34/share. According to their observations and findings, the stock could provide a high EPS of $0.35/share and a low EPS of $0.32/share.

Analysts believe that the company has the potential to earn average revenue of $2.36 Billion for the current quarter. According to their predictions high & low revenue estimates are 2.41 Billion and 2.32 Billion respectively.

Technical Analysis

By taking a look at the stock’s current statistics it can gauged that the stock candle is BEARISH with HIGH volatility. Boston Scientific Corporation (NYSE:BSX) has a 20-Day average volume of 9.34 Million. According to today’s trading volume Boston Scientific Corporation is BELOW its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BULLISH territory while an analysis of the last 40-Day trend shows a BEARISH signal. The 100-Day trend also shows a BEARISH trend as well.

The company currently has an insider ownership of 0.1 Percent and Institutional ownership of 94.3 Percent. The return on assets stands at 4.6%, Return on Equity currently is 11.8% and the Return on Investment value is 5.1%.

Boston Scientific Corporation (NYSE:BSX) gross margin percentage stands at 71.8% while its operating margin for the past trailing twelve month is 12.5 percent and its overall profit margin (ttm) is 9.5 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 6.87% with a 50-Day Simple Moving Average of 2.82 percent. As of today, the company has a SMA200 (200-day simple moving average) of 1 Percent. The Stock has YTD (year to date) performance of 10.65 percent.

The TTM operating margin for the company stands at 12.5%. The return on invested capital is at 5.1%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 47.1.

The company’s stock is currently moving with a +ve distance from the 200 day SMA of approximately 1%, and has a solid year to date (YTD) performance of 10.65% which means that the stock is constantly adding to its value from the previous fiscal year end price.